SCHEMBL2943033

SCHEMBL2943033

CSc1ccc2c(ccn2CCC(C)(C)NC(=O)OC(C)(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.40
▸ MTNR1A P48039 4/20 0.38
▸ MTNR1B P49286 4/20 0.38
▸ TP53 P04637 2/20 0.36
▸ MCL1 Q07820 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ TUBB4A P04350 2/20 0.33
▸ TUBB P07437 2/20 0.33
▸ TUBA3C P0DPH7 2/20 0.33
▸ TUBA1B P68363 2/20 0.33
▸ TUBA4A P68366 2/20 0.33
▸ TUBB4B P68371 2/20 0.33
▸ TUBB3 Q13509 2/20 0.33
▸ TUBB2A Q13885 2/20 0.33
▸ TUBB8 Q3ZCM7 2/20 0.33
▸ TUBA3E Q6PEY2 2/20 0.33
▸ TUBA1A Q71U36 2/20 0.33
▸ TUBA1C Q9BQE3 2/20 0.33
▸ TUBB6 Q9BUF5 2/20 0.33
▸ TUBB2B Q9BVA1 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2948637 0.83 CYP2A6 (0.44) MTNR1AMTNR1BTUBB4ATUBBTUBA3C
SCHEMBL2951656 0.83 DRD2 (0.40) MTNR1AMTNR1BTSHRHTT
SCHEMBL4748489 0.82 AR (0.42) BRD4MTNR1AMTNR1BMAPK1
SCHEMBL2950156 0.74 PLG (0.38) TP53
Hydrochloric Acid SCHEMBL2948588 0.73 PLG (0.38) TP53
SCHEMBL3414185 0.72 MTNR1A (0.46) BRD4MTNR1AMTNR1BTP53TSHR
SCHEMBL18935522 0.70 MTNR1A (0.51) BRD4MTNR1AMTNR1BTP53TSHR
SCHEMBL3417837 0.69 MTNR1A (0.50) BRD4MTNR1AMTNR1BTP53TSHR
SCHEMBL19778028 0.69 KMT2A (0.57) TP53ITGB2ICAM1ITGAL
SCHEMBL18917701 0.67 MTNR1A (0.48) MTNR1AMTNR1BTP53TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754756-B2 Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-13 — — US disclosed
EP-1943220-A2 NOVEL INDOLE-CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS Boehringer Ingelheim International GmbH (DE) 2008-07-16 — — EP disclosed
US-20070105906-A1 Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-10 — — US disclosed
WO-2007048841-A2 NOVEL INDOLE-CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105906-A1 Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions ADRB1, ADRB3, ADRB2 BRD4 3605/4885MTNR1A 51/4885MTNR1B 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback